Found 96 clinical trials
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2/NEU NEGATIVE BREAST CANCER.
PHASE III RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL EVALUATING THE USE OF ADJUVANT ENDOCRINE THERAPY +/- ONE YEAR OF EVEROLIMUS IN PATIENTS WITH HIGH-RISK, HORMONE RECEPTOR-POSITIVE AND HER2
- 220 views
- 24 Nov, 2020
- 1 location
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of Subjects with Advanced Renal Cell Carcinoma
A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First Line Treatment of
- 220 views
- 25 Mar, 2021
- 1 location
ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an investigational bioabsorbable vascular scaffold manufactured by Abbott. Absorb™ is referred to as a scaffold to indicate that it is a temporary structure.
ABSORB III - A Clinical Evaluation of Absorb™ BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects with de novo Native Coronary Artery Lesions Absorb™ is an
- 120 views
- 25 Mar, 2021
- 1 location
ABSORB III - Randomized Controlled Trial
ABSORB III - Randomized Controlled Trial
- 230 views
- 08 Nov, 2020
- 1 location
Itacitinib + Everolimus in Hodgkin Lymphoma
This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).
- 1 views
- 01 Aug, 2021
- 1 location
Pharmacokinetic Study on the Combination of Everolimus-Tacrolimus
The purpose of this study is to address the pharmacokinetic (PK) profiles of everolimus and tacrolimus in combination in de novo kidney transplant recipients, comparing 1.5 and 3 mg per
- 13 views
- 07 Nov, 2020
- 1 location
Everolimus (RAD001) and Carboplatin in Pretreated Metastatic Breast Cancer
This is an open-label, mono-center phase I/II study designed to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of RAD001 in combination with carboplatin in taxane- and anthracycline-pretreated patients with progressive metastatic breast cancer. Additionally, the study is designed to characterize the safety, the tolerability and efficacy of …
- 22 views
- 07 Nov, 2020
- 1 location
Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL
This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or
- 13 views
- 04 Aug, 2021
- 10 locations
Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion
This study is design to compare two different strategies aiming to lessen the degree of the ongoing process of allograft injury either by removing tacrolimus from the maintenance immunosuppressive protocol or by reducing tacrolimus dose. The primary goal is to assess the change in renal function at 6 and 12 …
- 11 views
- 07 Nov, 2020
- 1 location
Everolimus in Treating Patients With Recurrent or Progressive Low-Grade Glioma
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is
- 14 views
- 07 Nov, 2020
- 1 location